Andrew Trister via GitHub

Key Ap­ple dig­i­tal health re­searcher set to join the Gates Foun­da­tion — re­port

Last week, Ap­ple re­vealed it was work­ing with Eli Lil­ly on de­tect­ing de­men­tia in its ear­ly stages — and now a co-au­thor of the study is re­port­ed­ly head­ing to the Bill and Melin­da Gates Foun­da­tion.

The sci­en­tist, An­drew Tris­ter, joined Ap­ple in April 2016 in a ‘spe­cial projects’ role — be­fore the tech gi­ant’s big am­bi­tions in health care were thrust in­to the spot­light.

In an in­ter­view with CN­BC on Fri­day, Tris­ter con­firmed he was de­part­ing to take on the role of dig­i­tal health in­no­va­tion at the Gates Foun­da­tion — where he is set to work with en­tre­pre­neurs that are think­ing of bring­ing dig­i­tal health tech­nolo­gies from the Unit­ed States to de­vel­op­ing na­tions, where smart­phones are in­creas­ing­ly be­com­ing all-per­va­sive. In ad­di­tion, he will al­so in­vest in projects lo­cat­ed un­der-re­sourced re­gions, such as rur­al Africa and In­dia, the re­port said.

Af­ter serv­ing as a ra­di­a­tion on­col­o­gist at the Uni­ver­si­ty of Wash­ing­ton, Tris­ter took on the role of se­nior physi­cian at a non­prof­it that helps en­gag­ing pa­tients in med­ical re­search called Sage Bionet­works. In 2014, he joined Seat­tle’s Fred Hutchin­son Can­cer Re­search Cen­ter as a clin­i­cal re­searcher, be­fore sign­ing on with Ap­ple.

Ear­ly in 2019, Ap­ple $AAPL chief Tim Cook pre­dict­ed that in the fu­ture, his com­pa­ny’s great­est con­tri­bu­tion would be its im­pact on health. The lat­est it­er­a­tion of Ap­ple Watch con­tains a sim­ple elec­tro­car­dio­gram able to de­tect signs of atri­al fib­ril­la­tion (AFib) — a com­mon heart con­di­tion that rais­es the risk of stroke and is typ­i­cal­ly seen in the el­der­ly.

Ap­ple has sunk its talons in­to the health care in­dus­try, hav­ing forged re­la­tion­ships with acad­e­mia, drug/de­vice mak­ers and in­sur­ers. Apart from Lil­ly $LLY, the com­pa­ny has joined forces with John­son & John­son $JNJ to test the di­ag­no­sis and out­comes of AFib pa­tients in a clin­i­cal tri­al; last year it part­nered with med­ical de­vice mak­er Zim­mer Bio­met $ZBH in a bid to use the health da­ta cap­tured by the watch to de­ter­mine why some pa­tients re­cov­er faster from knee and hip re­place­ments; and in 2017, the com­pa­ny tied up with Stan­ford Uni­ver­si­ty to eval­u­ate pre­vi­ous edi­tions of the watch in a large-scale heart study.

But some of Ap­ple’s health re­cruits have left the iPhone mak­er in re­cent years. Last month, health in­sur­er An­them poached Ap­ple’s War­ris Bokhari; Last year, Ap­ple’s Robin Gold­stein de­part­ed for self-dri­ving start-up Zoox and Anil Sethi left to start health-tech com­pa­ny; and Stephen Friend made his ex­it in 2017 to be­come an in­de­pen­dent en­tre­pre­neur, CN­BC re­port­ed.

Gates en­tered the dis­as­ter-prone field of Alzheimer’s in late 2017, com­mit­ting $50 mil­lion of his non­prof­it foun­da­tion’s funds and a match­ing amount from his per­son­al for­tune to in­vest in a fresh ap­proach to fight the dis­ease — urg­ing re­searchers to go back to the draw­ing board in their quest to un­der­stand the eti­ol­o­gy of the dis­ease. Months ago, Ama­zon’s Jeff Be­zos and his es­tranged wife in­ject­ed $15 mil­lion to the $35 mil­lion haul Bill Gates raised for the di­ag­nos­tics work be­ing done by the Alzheimer’s Drug Dis­cov­ery Foun­da­tion.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

FDA to Sarep­ta: Your wide­ly an­tic­i­pat­ed fol­lowup to Ex­ondys 51 is not get­ting an ac­cel­er­at­ed OK for Duchenne MD

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with the US agency, which on Monday approved its other drug for community-acquired bacterial pneumonia.

The drug, lefamulin, has been developed as an intravenous and oral formulation and been tested in two late-stage clinical trials. The semi-synthetic compound, whose dosing can be switched between the two formulations, is engineered to inhibit the synthesis of bacterial protein by binding to a part of the bacterial ribosome.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.